Special Issue "Antiprotozoal Marine Natural Products"
A special issue of Marine Drugs (ISSN 1660-3397).
Deadline for manuscript submissions: closed (10 December 2017)
Prof. Dr. Deniz Tasdemir
GEOMAR Helmholtz Centre for Ocean Research Kiel, Head, Marine Natural Products Chemistry Research Unit, Director, GEOMAR Centre for Marine Biotechnology (GEOMAR-Biotech), Am Kiel-Kanal 44, Kiel 24106, Germany
Website | E-Mail
Fax: +49 431 600 4441
Interests: marine natural product chemistry; marine microbiology; deep-sea organisms; structure elucidation; bioactivity; cancer; infectious diseases
Protozoa are a large group of unicellular eukaryotic organisms. Some protozoans are parasitic and when transmitted to human (generally via an insect vector) cause serious infectious diseases, such as malaria, sleeping sickness, Chagas’ disease, toxoplasmosis. Many of these diseases are ancient, but still pose a significant threat to global health, particularly to those populations living in tropical and subtropical areas of the world. In the absence of vaccines, the control of the protozoans has relied on chemotherapy. Natural products play a key role in the eradication of protozoal infections, particularly in malaria where almost all antimalarial drugs can be traced to a natural product scaffold. Despite the short history, marine resources have also proven to be an excellent source for antiprotozoal lead compounds, such as manzamines, plakortins and sesquiterpenoids with isonitrile function, to name a few.
This special issue dedicated to “Antiprotozoal Marine Natural Products” aims to emphasize the importance of novel approaches; discovery of new or understudied sources and novel molecules from marine flora and fauna to tackle these diseases. Marine microorganisms are also included, as in some cases, they are the true source of antiparasitic compounds.
As the Guest Editor, I encourage all scientists to submit their latest research findings in this area. I hope that it will contribute to future drug discovery efforts on protozoal infections, many of which are still placed under the category of ‘neglected diseases’.
Prof. Dr. Deniz Tasdemir
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- marine natural product
- marine invertebrate
- marine microorganism
- marine alga
- antiprotozoal marine natural product
- protozoal infection
- sleeping sickness
- Chagas’ disease
- drug discovery